Drug intelligence / Profile preview

BDlenti-dAMD

Development stage: Preclinical
Lead developer: Shanghai BDgene Therapeutics
Modality: Gene Therapies
Administration: Ophthalmic

Overview

BDlenti-dAMD is a preclinical gene therapy candidate developed by Shanghai BDgene Therapeutics for the treatment of dry age-related macular degeneration (dAMD). Utilizing the company's proprietary BDlenti platform, the therapy employs a lentiviral vector for gene addition. While the specific transgene and molecular target have not been publicly disclosed, the program aims to address the underlying pathology of dAMD, a leading cause of vision loss characterized by the progressive degeneration of the retinal pigment epithelium and photoreceptors.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on BDlenti-dAMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDlenti-dAMD.

Explore the full profile